Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMMU-107 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| multiple dose levels | EXPERIMENTAL | 1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine. |
| Name | Type | Description |
|---|---|---|
| IMMU-107 (hPAM4) | BIOLOGICAL | 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks |
Inclusion Criteria: * Male or female patients, \>18 years of age, who are able to understand and give written informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Stage III (locally advanced, unresectable) or Stage IV (metastatic) disease, including patients wh...
Top 20 of 68 competitors
IMMU-107 is a monoclonal antibody being investigated for the treatment of pancreatic cancer. It is currently in Phase 1 clinical development, meaning it is still investigational and has not been approved for use. The drug is being studied in combination with gemcitabine in patients with pancreatic cancer.
IMMU-107 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody for pancreatic cancer.
IMMU-107 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials according to available data.
IMMU-107 has been studied in one clinical trial with the identifier NCT00603863, titled 'Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer.' This Phase 1 trial enrolled 80 participants in the United States and has been completed.
IMMU-107 is associated with the investigational agent 90Y-hPAM4, as indicated by the clinical trial title. The trial studied different doses of 90Y-hPAM4 combined with gemcitabine in pancreatic cancer. This suggests IMMU-107 may be the same compound as 90Y-hPAM4, though the exact relationship is not specified.